APICES acknowledged for its remarkable role in PALBOBIN clinical trial
We are proud to announce that APICES has been acknowledged for its ongoing collaboration in PALBOBIN Trial, a Phase IB clinical trial in Breast Cancer (TNBC). This acknowledgement was highlighted in the Journal of Cancer Research Communications.
APICES has contributed extensively to critical aspects throughout the trial, including start-up, coordination, project management, monitoring, and data management activities.
This acknowledgment is a great motivation for the entire APICES team to continue the commitment we bring to every project we collaborate on. We would like to congratulate to Ana Moreno, Susana Vara, Juan Luis Sanz and other colleagues from our Spain team involved in this trial. Your hard work and dedication make a real difference, and we are proud to have you representing APICES CRO in such impactful research.
We also sincerely thank PFIZER and Dr. Luis Manso for giving us the opportunity to support the study as CRO and for including us acknowledgments. We also congratulate them and all investigators and patients on the CABOMAYOR trial progress and results.
The PALBOBIN Trial was aimed at to evaluate palbociclib and binimetinib in advanced Breast Cancer TNBC after one or two prior therapies. Advanced, pre-treated TNBC has a dismal prognosis and lacks effective options beyond standard cytotoxics. We previously showed, via phosphoproteomic screening, that CDK6 and ERK hyperactivation are linked to adverse outcomes and represent actionable targets.
For further information about the PALBOBIN Trial, please visit: A phase IB study of binimetinib and palbociclib in molecularly selected advanced triple-negative breast cancer. | Cancer Research Communications | American Association for Cancer Research
